TROY CARR: Open Payments
NPI 1275250102 · NAMPA, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,223 in 74 payments from 14 companies in 2025. Trend: 2023 $1,233 · 2024 $1,425 · 2025 $1,223
Food & beverage: $1,223
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 39 | $405 |
| Madrigal Pharmaceuticals | 8 | $213 |
| GENZYME CORPORATION | 6 | $129 |
| GlaxoSmithKline, LLC. | 1 | $95 |
| Regeneron Healthcare Solutions, Inc. | 4 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $64 |
| PFIZER INC. | 4 | $63 |
| Aimmune Therapeutics, Inc. | 2 | $41 |
| Celltrion USA Inc. | 2 | $34 |
| Janssen Biotech, Inc. | 1 | $28 |
Products named: RINVOQ, REZDIFFRA, DUPIXENT, SKYRIZI, VELSIPITY, CREON, ZENPEP, ENTYVIO.
Industry payments across ID — which companies pay providers there.
